Viridian Therapeutics, Inc.\DE (VRDN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Viridian Therapeutics, Inc.\DE reported revenue of $70.8M, up 23359.9% from $302,000 the year before. Net income was -$342.6M (a -483.6% net margin). Operating margin was -512.9%. Operating activities generated -$276.4M of cash, leaving -$276.9M of free cash flow. At fiscal year end, Viridian Therapeutics, Inc.\DE held $899.4M in total assets against $177.3M in total liabilities.
Open the full interactive Viridian Therapeutics, Inc.\DE financials → Quarterly statements, key ratios, valuation history and price charts.
Viridian Therapeutics, Inc.\DE Key Stats
| Share Price | $18.22 |
|---|---|
| 52-Week Range | $13.30 – $33.78 |
| Shares Outstanding | 66.4 million (basic, 2024 Q3) |
Viridian Therapeutics, Inc.\DE Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $3.0M | $1.8M | $314,000 | $302,000 | $70.8M |
| Operating Income | -$110.4M | -$79.7M | -$134.3M | -$254.4M | -$299.0M | -$363.4M |
| Pre-Tax Income | -$110.7M | -$79.4M | -$129.9M | -$237.7M | -$269.9M | -$342.6M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$110.7M | -$79.4M | -$129.9M | -$237.7M | -$269.9M | -$342.6M |
| Diluted EPS | -$31.13 | -$6.66 | -$4.05 | -$5.31 | — | — |
Viridian Therapeutics, Inc.\DE Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $70.6M | $132,000 | $141,000 | $284,000 |
| Net Income | -$34.6M | -$120.4M | -$104.9M | -$127.1M |
Viridian Therapeutics, Inc.\DE Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Current Assets | $129.6M | $200.2M | $431.2M | $486.5M | $738.5M | $894.2M |
| Total Assets | $131.3M | $203.7M | $435.1M | $490.4M | $742.4M | $899.4M |
| Current Liabilities | $10.7M | $13.6M | $33.3M | $26.6M | $47.9M | $70.7M |
| Total Long-Term Debt | — | — | $4.6M | $20.2M | $20.6M | $84.2M |
| Total Liabilities | $11.2M | $16.0M | $40.0M | $48.4M | $70.8M | $177.3M |
| Shareholders' Equity | $120.0M | $187.7M | $395.1M | $442.0M | $671.6M | $722.2M |
Viridian Therapeutics, Inc.\DE Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$29.8M | -$54.6M | -$93.8M | -$184.2M | -$232.3M | -$276.4M |
| Cash From Investing | -$50.5M | -$74.3M | -$115.1M | -$94.3M | -$228.7M | -$37.6M |
| Cash From Financing | $101.3M | $125.3M | $322.2M | $225.7M | $457.7M | $426.7M |
| Free Cash Flow | -$29.8M | -$54.9M | -$94.6M | -$185.1M | -$232.8M | -$276.9M |
Figures from Viridian Therapeutics, Inc.\DE's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Viridian Therapeutics, Inc.\DE financials page for every line item.
Viridian Therapeutics, Inc.\DE Company Profile
| Ticker | VRDN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001590750 |
Frequently Asked Questions
What was Viridian Therapeutics, Inc.\DE's revenue in fiscal 2025?
Viridian Therapeutics, Inc.\DE (VRDN) reported revenue of $70.8M for fiscal 2025.
What is Viridian Therapeutics, Inc.\DE's annual revenue history?
Viridian Therapeutics, Inc.\DE's annual revenue by fiscal year: 2020: $1.1M; 2021: $3.0M; 2022: $1.8M; 2023: $314,000; 2024: $302,000; 2025: $70.8M.
What was Viridian Therapeutics, Inc.\DE's net income in fiscal 2025?
Viridian Therapeutics, Inc.\DE reported net income of -$342.6M for fiscal 2025.
How much free cash flow did Viridian Therapeutics, Inc.\DE generate in fiscal 2025?
Viridian Therapeutics, Inc.\DE generated -$276.9M of free cash flow in fiscal 2025.
What was Viridian Therapeutics, Inc.\DE's revenue last quarter?
In its most recent reported quarter (2026 Q2), Viridian Therapeutics, Inc.\DE reported revenue of $284,000.
How much debt does Viridian Therapeutics, Inc.\DE have?
Viridian Therapeutics, Inc.\DE reported $84.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Viridian Therapeutics, Inc.\DE are outstanding?
Viridian Therapeutics, Inc.\DE reported a weighted average of 66.4 million basic shares outstanding in 2024 Q3.
When does Viridian Therapeutics, Inc.\DE's fiscal year end?
Viridian Therapeutics, Inc.\DE's fiscal year end, as registered with the SEC, is December 31.
Where is Viridian Therapeutics, Inc.\DE headquartered?
Viridian Therapeutics, Inc.\DE lists its business address in Waltham, Massachusetts in its SEC filings.